A Phase 2/3 interventional study of Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution and Placebo in Pseudophakic Bullous Keratopathy and Glaucoma, sponsored by University Hospital Dubrava. Completed at 1 site in Croatia. Open to participants aged 40 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by University Hospital Dubrava · Phase 2/3, Interventional, and Treatment
The goal of this clinical trial is to learn if topical netarsudil/latanoprost works to treat pseudophakic bullous keratopathy in patients with glaucoma. The main questions it aims to answer are:
Does topical netarsudil/latanoprost improves visual function in patients with glaucoma and pseudophakic bullous keratopathy? Does topical netarsudil/latanoprost affects the central corneal thickness (CCT) in patients with glaucoma and pseudophakic bullous keratopathy? Researchers will compare topical netarsudil/latanoprost to a placebo (a look-alike substance that contains no drug) to see if topical netarsudil/latanoprost works to treat pseudophakic bullous keratopathy (PBK).
Participants will take topical netarsudil/latanoprost or a placebo every day for 12 weeks and visit the clinic once every two weeks for checkups and tests.
Patients with glaucoma and pseudophakic bullous keratopathy will be randomly divided in two groups. Group 1 will take topical netarsudil/latanoprost 1x daily for 3 months and group 2 will take topical placebo (artificial tear substitute) 1x daily for 3 months. Visual acuity (VA) will be evaluated using Snellen chart and converted to logarithm of the minimum angle of resolution (LogMAR). Central corneal thickness (CCT) measurements will be performed using OCT (Optovue Ivue). Information about intraocular pressure and adverse effects will be recorded during the study. Patients will visit every two weeks for checkups and measurements for 12 weeks.
1,818 studies on the registry are indexed under Glaucoma; 231 are open to participants now.
This study's enrollment of 50 is below the median of 65 across 1,272 interventional studies indexed under Glaucoma.
Browse Glaucoma studies →University Hospital Dubrava is the lead sponsor of 39 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Group 1 or ROCK inhibitor group will receive topical netarsudil/latanoprost 1x daily for 12 weeks.
Drug: Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution
Placebo group will receive topical placebo (artificial tear substitute) 1x daily for 12 weeks.
Drug: Placebo
Patients with pseudophakic bullous keratopthy and glaucoma will receive topical netarsudil/latanoprost 1x daily for 12 weeks.
Patients with pseudophakic bullous keratopathy and glaucoma will receive topical placebo 8artificial tear substitute) 1x daily for 12 weeks.
Visual acuity (VA)
Visual acuity measurements using Snellen chart and converted to logMAR
Time frame: 12 weeks
Central corneal thickness (CCT)
CCT will be measured using OCT (Optovue iVue)
Time frame: 12 weeks
Plan to share: No — This study does not plan to share individual participant data.
No publications or documents are linked to this record.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital Dubrava